Abstract. Pathological response to preoperative chemotherapy was recently found to be correlated with improved survival and has been proposed as a new outcome end-point following resection of liver metastases from colorectal cancer (CRC). It was demonstrated that, particularly after therapy with bevacizumab, CRC liver metastases decreased in size and underwent distinct morphological changes on computed tomography (CT). However, morphological changes in response to treatment with regorafenib have not yet been reported. A 74-year-old male patient with synchronous multiple liver and lung metastases from colon cancer was treated with regorafenib as a fifth-line therapy. CT imaging revealed a decrease in the tumor size and distinct morphological changes, namely homogeneous attenuation and sharp tumor-liver interface. The patient continued to take regorafenib for 8 months. Thus, regorafenib appeared to be effective as a last-line chemotherapy. In particular, the unique morphological changes of the metastases on CT imaging of may represent a method for evaluating the effects of CRC cancer therapy.
Introduction
Regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals) is an orally administered multikinase inhibitor. Preclinical studies demonstrated that regorafenib targets cell signaling pathways involved in tumor formation and progression, including inhibition of protein kinases associated with angiogenesis [e.g., vascular endothelial growth factor receptor (VEGFR) 1-3 and TIE2], oncogenesis (e.g., KIT and RET), and maintainance of the tumor microenvironment (e.g., platelet-derived growth factor receptor and fibroblast growth factor receptor) (1, 2) .
At present, regorafenib has been approved for use following 3rd-line therapy for metastatic colorectal cancer (CRC) (3) . As shown by computed tomography (CT) imaging, last-line chemotherapy is often ineffective. In the present case, treatment with regorafenib was indicated based on the presence of synchronous multiple lung and liver metastases from colon cancer and CT imaging revealed a significant change in tumor size. We herein report the patient's clinical course and CT imaging findings.
Case presentation
A 74-year-old male patient with sigmoid colon cancer and synchronous lung and liver metastases (stage IV) was treated with high anterior resection and D3 lymphadenectomy. The patient had undergone 16 courses of FOLFOX + bevacizumab (BV) as postoperative first-line therapy. Due to disease progression, follow-up treatment with 19 courses of BV + FOLFIRI was administered as a second-line therapy. The patient's performance status (PS) worsened to 2 due to the side effects of chemotherapy (general fatigue and edema). The disease continued to progress and the patient was administered 14 courses of panitumumab (an agent with anti-epidermal growth factor receptor activity in patients with wild-type Kras) as third-line chemotherapy, and the PS improved from 2 to 1. The disease progressed further and the patient underwent fourth-line chemotherapy comprising three courses of panitumumab plus irinotecan; however disease progression continued. Regorafenib was then administered as the last-line (fifth-line) therapy, the patient's side effects gradually subsided and the disease stabilized. The tumor size (liver and lung) decreased and morphological changes were revealed by CT imaging. In addition, the levels of the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 decreased in parallel with the changes in tumor morphology (Figs. 1-3 ). The patient continued to receive regorafenib for 8 months. As proteinuria (+++) appeared during the clinical course, the dose of regorafenib was gradually reduced from 160 to 80 mg, while repeating stop-and-go therapy. Although the condition improved with the dose reduction and the stop-and-go therapy, nephrotic syndrome ultimately developed (Fig. 3) . The patient eventually succumbed to nephrotic syndrome and cardiac failure from the original disease at 3 years and 10 months after the initiation of first-line chemotherapy. Written informed consent was obtained from the patient for the publication of this case report and accompanying images.
Discussion
Chemotherapy has played a pivotal role in the multidisciplinary management of colorectal liver metastases (CLM). Systemic chemotherapy may reduce the size of metastases, increase their resectability, and may also help select patients who are most likely to benefit from surgery by assessing tumor response to chemotherapy (4, 5) . However, the conventional tumor size-based radiological Response Evaluation Criteria in Solid Tumours (RECIST) may be inadequate for assessing the response to chemotherapy (6), particularly in patients treated with a regimen such as BV, which interferes with angiogenesis. The pathological response to preoperative chemotherapy was recently found to be correlated with improved survival and has been proposed as a new outcome end-point following resection of CLM (7, 8) . In particular, Shindoh et al (9) reported that, following therapy containing BV, the CLM tended to decrease in size and also underwent distinct morphological changes on CT, namely homogeneous attenuation and sharp tumor-liver interface. Recently, chemotherapy for CRC has markedly progressed. In particular, the treatment for advanced or metastatic CRC has significantly improved due to the development of the FOLFOX and FOLFIRI regimens. Furthermore, the introduction of targeted therapy has made the treatment of CRC patients more effective (10).
Regorafenib is the first small-molecule multikinase inhibitor to offer a survival benefit in metastatic CRC that has progressed after all standard therapies. In the CORRECT study, no patients achieved a complete response; however, 5 patients receiving regorafenib and 1 patient assigned to placebo exhibited a partial response, with objective response rates of 1.0 and 0.4%, respectively (P=0.19) (3) . As complete and partial responses were obtained in only a few patients, regorafenib is unlikely to achieve complete or partial disease response. However, disease control was achieved in 41% of the patients assigned regorafenib and 15% of the patients assigned a placebo (P<0.0001). The median duration of stable disease was 2.0 months in the regorafenib group and 1.7 months in the placebo group. These data indicate that regorafenib as last-line chemotherapy is unlikely to produce effective results on imaging (RECIST, version1.1) (6). However, the results of the present study indicated that evaluation of liver metastases by CT may be effective (10) .
The end-point in cancer research is overall survival; however, tumor response and time to progression are considered pivotal for surrogate assessment of treatment efficacy. Tumor response was initially assessed according to the World Health Organization (WHO) criteria, and later according to the RECIST guidelines (11) . WHO and RECIST define standard measurement methods for converting radiological observations into a quantitative and statistically tractable framework for measuring the response of tumor size to therapy. Both methods offer simple approaches to determining anatomical size and changes during treatment as indicators of response (12, 13) . Target lesions may be measured with either the bilinear product approach (WHO) or the single linear summation (RECIST) (14) (15) (16) . Of note, following anti-VEGF antigen-containing therapy, CRC metastases not only tend to decrease in size, but also undergo distinct morphological changes on CT (9). Initially, the morphological changes on CT in our patient indicated a response to regorafenib. These changes may prolong overall survival and improve the quality of life. However, in a number of patients, morphological changes do not result in any change in tumor size; therefore, they are not suitable for evaluation according to RECIST. Evaluation of chemotherapeutic response following regorafenib and anti-VEGF antigen therapy were included in the modified RECIST (mRECIST) guidelines, which were developed to assess response in patients with hepatocellular carcinoma based on the measurement of viable tumor with arterial enhancement on CT. The guidelines of mRECIST were evaluated and compared with those in RECIST for patients who received sorafenib for advanced hepatocellular carcinoma. The mRECIST guidelines for hepatocellular carcinoma introduced amendments to RECIST for the determination of tumor response in target lesions. The majority of the patients with stable disease according to RECIST had a different prognosis according to mRECIST. We recommend that a suitable CT scan evaluation according to mRECIST guidelines is performed in patients with CLM. mRECIST should be used for the standard assessment of treatment efficacy, particularly in patients receiving regorafenib.
In conclusion, regorafenib appeared to be effective as a last-line chemotherapy treatment in a patient with sigmoid colon cancer and synchronous lung and liver metastases. Identifying unique morphological changes of metastatic lesions on CT imaging may be a suitable method for evaluating the effects of treatment in CRC.
